Login to Your Account



Pharma: Other News To Note


Monday, April 9, 2012
• Astellas Pharma Inc., of Tokyo, said the FDA's Reproductive Health Drugs Advisory Committee voted 7 to 4, with one abstention, that the overall risk/benefit assessment supported approval of mirabegron (YM178) in overactive bladder. The FDA is not bound to follow the recommendation of advisory panels, but the agency generally does so. Mirabegron's PDUFA date is June 29.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription